The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 345:545-546 August 16, 2001 Number 7
NextNext

A Salmonella typhi Vi Conjugate Vaccine

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: In their article on the polysaccharide conjugate typhoid vaccine Vi-rEPA, Lin et al. (April 26 issue)1 report an efficacy of 91.5 percent in the prevention of typhoid fever due to the development of IgG Vi antibodies, and they presume that the vaccination can help in the prevention of typhoid fever and in limiting the spread of multidrug-resistant enteric fever.

There were five cases of typhoid fever in the vaccine group, even though the serum levels of IgG Vi antibodies increased by a factor of at least 10 in 100 percent of the children. The levels of IgG . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.